Targeted Therapies: The Rare Cancer Paradigm

Response to imatinib plus sirolimus in advanced chordoma

(2009) S. Stacchiotti et al.   ANNALS OF ONCOLOGY

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

(2009) A Oden-Gangloff et al.   BRITISH JOURNAL OF CANCER

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

(2009) F Loupakis et al.   BRITISH JOURNAL OF CANCER

Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors

(2009) Keith M. Skubitz et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

(2009) A. Sartore-Bianchi et al.   CANCER RESEARCH

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

(2009) H. Prenen et al.   CLINICAL CANCER RESEARCH

Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma

(2009) S. Stacchiotti et al.   CLINICAL CANCER RESEARCH

Giant cell tumour of bone

(2009) David M Thomas et al.   CURRENT OPINION IN ONCOLOGY

Ewing’s Sarcoma: Standard and Experimental Treatment Options

(2009) Vivek Subbiah et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Desmoid tumors: need for an individualized approach

(2009) Eelco de Bree et al.   Expert Review of Anticancer Therapy

Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications

(2009) Beatriz Llombart et al.   HISTOPATHOLOGY

Current treatment options in dermatofibrosarcoma protuberans

(2009) Doreen Lemm et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

(2009) Fotios Loupakis et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection

(2009) Antonio Jimeno et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Vulnerability of an In Vivo Model of Alveolar Soft Part Sarcoma (ASPS) to Antiangiogenic Therapy

(2009) David T. Vistica et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

T670X KIT Mutations in Gastrointestinal Stromal Tumors: Making Sense of Missense

(2009) T. Negri et al.   JNCI-Journal of the National Cancer Institute

A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma

(2009) Hayriye V Erkizan et al.   NATURE MEDICINE

Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib

(2008) Ola Lindèn et al.   ACTA ONCOLOGICA

Specific Mutations in the β-Catenin Gene (CTNNB1) Correlate with Local Recurrence in Sporadic Desmoid Tumors

(2008) Alexander J.F. Lazar et al.   AMERICAN JOURNAL OF PATHOLOGY

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

(2008) F. Perrone et al.   ANNALS OF ONCOLOGY

Molecular Pathobiology of Gastrointestinal Stromal Sarcomas

(2008) Christopher L. Corless et al.   Annual Review of Pathology-Mechanisms of Disease

Systemic therapy for metastatic colorectal cancer

(2008) Dan S. Zuckerman et al.   CANCER

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

(2008) M. C. Heinrich et al.   CLINICAL CANCER RESEARCH

Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study

(2008) N. Personeni et al.   CLINICAL CANCER RESEARCH

Dermatofibrosarcoma protuberans

(2008) Vassilios A. Dimitropoulos   Dermatologic Therapy

Clinical significance of oncogenicKITandPDGFRAmutations in gastrointestinal stromal tumours

(2008) J Lasota et al.   HISTOPATHOLOGY

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes

(2008) A Bheda et al.   ONCOGENE